Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Companion Diagnostics (CDx) Market Report 2024-2034 - High Capital Investment and Low Cost-benefit Ratio to Challenge Industry Growth | ||
By: PR Newswire Association LLC. - 09 Feb 2024 | Back to overview list |
|
DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Companion Diagnostics (CDx) Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for Companion Diagnostics (CDx) Market is forecast to surpass US$6.5 billion in 2024, with strong revenue growth through to 2034. The market for CDx is expanding thanks in large part to technological developments. Better, more sensitive, and more focused CDx tests are coming from these developments. Important technical developments in CDx include the following:-
These technological improvements are having a significant impact on the CDx industry and are projected to fuel market expansion in the coming years. CDx tests are getting more accurate, sensitive, and inexpensive as a result of these improvements, and they are playing an increasingly essential role in personalised medicine. In 2023, a number of significant businesses plan to make significant investments in companion diagnostics. Here are few instances:-
Hence, these improvements and new product introductions highlight the CDx market's dynamic nature and its potential to revolutionise cancer therapy by providing precision medicine. High Capital Investment and Low Cost-benefit Ratio Likely to Challenge Industry Growth These specialised tests require significant capital expenditure to design and validate. Companion diagnostics, in contrast to more general diagnostic instruments, serve a specific and narrower population. This indicates that the market may not be as large as expected, which would make it difficult to recover the high expenses associated with R&D and obtaining necessary permits. These tests also frequently need for advanced infrastructure and technologies, which raises the cost even further. The development and validation of these specialised tests necessitates substantial capital commitment. Companion diagnostics, as opposed to broader diagnostic instruments, target a smaller, more specific group. As a result, the market size may be limited, making it difficult to recoup the significant expenditures of research, development, and regulatory approvals. Furthermore, these examinations frequently necessitate expensive technology and infrastructure, which increases the budgetary load. However, calculating the cost-benefit ratio might be difficult. Companion diagnostics have the potential to improve treatment efficacy and reduce waste by ensuring that the right patients receive the proper treatment. This can result in cost reductions for healthcare systems as well as better patient outcomes. However, realising these benefits is contingent on a number of circumstances, including the prevalence of the targeted group, the efficacy of the companion medication, and the cost of the test itself. When the target population is small or the diagnostic cost is high, the cost-benefit ratio may be skewed to the negative. Manufacturers may be discouraged from investing in companion diagnostics, even if they provide great therapeutic value. Key Market Dynamics Market Driving Factors
Market Restraining Factors
Market Opportunities
Segments Covered in the Report Product & Services:
Technology:
Indication:
End-users:
Leading Companies profiled in the report:
Forecasts to 2034 and other analyses reveal commercial prospects:
For more information about this report visit https://www.researchandmarkets.com/r/9zhaw4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets For E.S.T Office Hours Call +1-917-300-0470 U.S. Fax: 646-607-1904 Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg View original content:https://www.prnewswire.com/news-releases/companion-diagnostics-cdx-market-report-2024-2034---high-capital-investment-and-low-cost-benefit-ratio-to-challenge-industry-growth-302058461.html SOURCE Research and Markets |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |